MA40386A - Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci - Google Patents

Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci

Info

Publication number
MA40386A
MA40386A MA040386A MA40386A MA40386A MA 40386 A MA40386 A MA 40386A MA 040386 A MA040386 A MA 040386A MA 40386 A MA40386 A MA 40386A MA 40386 A MA40386 A MA 40386A
Authority
MA
Morocco
Prior art keywords
analogs
cabozantinib
preparing fluorine
labeled
preparing
Prior art date
Application number
MA040386A
Other languages
English (en)
Inventor
Patrick L Chow
David J Donnelly
Benjamin J Henley
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA40386A publication Critical patent/MA40386A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un procédé de préparation de cabozantinib ([4- (6,7-diméthoxy-quinolin-4-yloxy)phénylo]amide-(4-fluoro-phényl)amide) d'acide cyclopropane-1,1-dicarboxylique) et de cabozantinib marqué au
MA040386A 2014-07-31 2015-07-31 Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci MA40386A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462031471P 2014-07-31 2014-07-31

Publications (1)

Publication Number Publication Date
MA40386A true MA40386A (fr) 2016-02-04

Family

ID=54072944

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040386A MA40386A (fr) 2014-07-31 2015-07-31 Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci

Country Status (9)

Country Link
US (2) US11124481B2 (fr)
EP (1) EP3174854B1 (fr)
JP (2) JP6789923B2 (fr)
CN (1) CN106715397B (fr)
CA (1) CA2956810C (fr)
EA (1) EA033834B1 (fr)
ES (1) ES2929888T3 (fr)
MA (1) MA40386A (fr)
WO (1) WO2016019285A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20196995B (en) * 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP3738952A1 (fr) 2014-02-14 2020-11-18 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
WO2015142928A1 (fr) 2014-03-17 2015-09-24 Exelixis, Inc. Dosage de préparations de cabozantinib
MA40386A (fr) * 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
EP3442531A1 (fr) 2016-04-15 2019-02-20 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN107556238A (zh) * 2016-06-30 2018-01-09 深圳万乐药业有限公司 一种卡博替尼的合成方法
GB201621864D0 (en) 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning
UA126402C2 (uk) * 2017-06-09 2022-09-28 Екселіксіс, Інк. Рідка лікарська форма для лікування раку
CN109836381A (zh) * 2017-11-29 2019-06-04 连云港恒运药业有限公司 多受体酪氨酸激酶抑制剂及其中间体的制备方法
CN109988107B (zh) * 2017-12-29 2022-01-14 江苏豪森药业集团有限公司 卡博替尼的制备方法
MY210421A (en) 2018-01-26 2025-09-22 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
CN110143917B (zh) * 2019-07-09 2020-03-31 郑州大学第一附属医院 一种卡博替尼代谢物的制备方法
CN110903240A (zh) * 2019-12-12 2020-03-24 上海玉函化工有限公司 一种广谱抗癌药卡博替尼的制备方法
KR20230005190A (ko) 2020-04-30 2023-01-09 엑셀리시스, 인코포레이티드 키나제억제제의 제조 공정
WO2023132352A1 (fr) * 2022-01-06 2023-07-13 中外製薬株式会社 Procédé de fabrication de composé amide
WO2024114710A1 (fr) * 2022-12-01 2024-06-06 江苏奥赛康药业有限公司 Procédé de préparation de cabozantinib et d'un intermédiaire de celui-ci
EP4658271A1 (fr) 2023-01-31 2025-12-10 Handa Oncology, LLC Compositions de cabozantinib améliorées et procédés d'utilisation
WO2025115975A1 (fr) * 2023-11-30 2025-06-05 日産化学株式会社 Procédé de production d'un composé amino aromatique

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260221A1 (en) * 2000-04-03 2001-10-15 Abb Ab A multiphase induction device
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
JP5368701B2 (ja) 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
CA2603748A1 (fr) 2005-04-06 2006-10-12 Exelixis, Inc. Modulateurs c-met modulators et procedes d'utilisation
JP2007056777A (ja) 2005-08-25 2007-03-08 Daido Steel Co Ltd 電磁駆動弁
US7790885B2 (en) * 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CN102282134B (zh) 2008-11-13 2015-04-01 埃克塞里艾克西斯公司 喹啉衍生物制备方法
WO2010065838A1 (fr) 2008-12-04 2010-06-10 Exelixis, Inc. Procédés de préparation de dérivés de quinoléine
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
EP2454238A1 (fr) 2009-07-17 2012-05-23 Exelixis, Inc. Formes cristallines du n [3 fluoro-4-({méthyloxy)-7-[(3-morpholin-4-yl- propyl)oxy]quinoléin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane- 1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN102933551A (zh) 2010-03-12 2013-02-13 埃克塞里艾克西斯公司 N-[3-氟-4-({6-(甲氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺的水合结晶形式
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2593091A1 (fr) 2010-07-16 2013-05-22 Exelixis, Inc. Compositions pharmaceutiques modulatrices de c-met
KR20180056807A (ko) 2010-07-16 2018-05-29 엑셀리시스, 인코포레이티드 C-met 조절제 약제학적 조성물
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
WO2012044574A1 (fr) 2010-09-27 2012-04-05 Exelixis, Inc. Inhibiteurs de met et vegf à double effet pour le traitement du cancer de la prostate résistant à la castration et des métastases osseuses ostéoblastiques
PL2621481T5 (pl) 2010-09-27 2023-03-13 Exelixis, Inc. Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości
JP2013543011A (ja) 2010-11-22 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌の治療法
CA2826751C (fr) 2011-02-10 2021-05-18 Exelixis, Inc. Procedes de synthese de quinoleines et compositions pharmaceutiques les incluant
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EP2758057B1 (fr) 2011-09-22 2017-05-31 Exelixis, Inc. Méthode de traitement de l'ostéoporose
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
KR20140088610A (ko) 2011-11-08 2014-07-10 엑셀리시스, 인코포레이티드 암을 치료하기 위한 met 및 vegf의 이중 저해제
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
WO2014039971A1 (fr) 2012-09-07 2014-03-13 Exelixis, Inc. Inhibiteurs de met, vegfr et ret pour l'utilisation dans le traitement d'un adénocarcinome du poumon
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
GEP20196995B (en) * 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) * 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
CN108472242A (zh) 2013-04-04 2018-08-31 埃克塞里艾克西斯公司 治疗癌症的药物组合
EP3738952A1 (fr) 2014-02-14 2020-11-18 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
WO2015142928A1 (fr) * 2014-03-17 2015-09-24 Exelixis, Inc. Dosage de préparations de cabozantinib
EP3906921A1 (fr) 2014-04-25 2021-11-10 Exelixis, Inc. Procédé de traitement de l'adénocarcinome pulmonaire
MA40386A (fr) * 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
US20170224670A1 (en) 2014-10-14 2017-08-10 Exelixis, Inc. Drug Combination to Treat Melanoma
US10501415B2 (en) 2015-04-07 2019-12-10 Unitika Ltd. Method for producing bisimide dicarboxylic acid
MX389966B (es) 2017-01-20 2025-03-20 Exelixis Inc Combinaciones de cabozantinib y atezolizumab para tratar cancer.

Also Published As

Publication number Publication date
CN106715397B (zh) 2021-07-23
EA201790286A1 (ru) 2017-06-30
US20170217896A1 (en) 2017-08-03
US20220194902A1 (en) 2022-06-23
CA2956810C (fr) 2022-10-04
EP3174854A1 (fr) 2017-06-07
EP3174854B1 (fr) 2022-08-24
JP2017523195A (ja) 2017-08-17
JP6789923B2 (ja) 2020-11-25
ES2929888T3 (es) 2022-12-02
JP2020186261A (ja) 2020-11-19
EA033834B1 (ru) 2019-11-29
CA2956810A1 (fr) 2016-02-04
CN106715397A (zh) 2017-05-24
US11124481B2 (en) 2021-09-21
WO2016019285A1 (fr) 2016-02-04

Similar Documents

Publication Publication Date Title
MA40386A (fr) Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
IN2014CH00247A (fr)
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
HUE059279T2 (hu) Eljárás alkének elõállítására és azok felhasználása 1,3-butadién elõállításához
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
WO2014125506A3 (fr) Procédé de préparation d'ivacaftor et de ses intermédiaires
MA40378A (fr) Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine
MY178422A (en) Process for preparing phosphorus-containing cyanohydrins
IN2013MU00848A (fr)
EP3122342A4 (fr) Procédé pour la préparation d'un amide de n-acétylcystéine
EP3265083A4 (fr) Analogues de depsipeptide d'urée substitués à utiliser en tant qu'activateurs de l'endopeptidase clpp
IN2013CH04906A (fr)
PL3073404T3 (pl) Sposób identyfikacji sygnatury interakcji użytkownika
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
ZA201803105B (en) Industrial process for the preparation of (5s,10s)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (e)-3-carboxyacrylate salt
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
SG11201608422VA (en) Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof
MX384260B (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MA40444A (fr) Procédé de préparation de formulations de poudre sèche
IL250260A0 (en) Process for preparing 4,5,6-trichloropicolinic acid
GEAP201814415A (en) Process for preparing the inhalation formulations
IN2013CH05865A (fr)
MA40443A (fr) Nouveau procédé de préparation de formulations de poudre sèche
IN2014MU01191A (fr)